AstraZeneca PLC American Depositary Shares (AZN)
AstraZeneca to face questions on Trump MFN deal, patent expiries and pipeline
When AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reports third-quarter results next Thursday, 6 November, with investors and analysts will be keen to hear about the financial implications of the 'most favoured nation' (MFN) pricing deal recently agreed with Donald Trump, as well as the loss of its Farxiga patent and prospects for new drugs coming out of its pipeline. This will be the first opportunity for discussion of the US MFN deal, making its a key discussion point, according to analysts at UBS.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Astrazeneca (AZN) closed at $82.61 in the latest trading session, marking a -1.72% move from the prior day.
AstraZeneca found in breach of industry code over Symbicort marketing, industry body says
AstraZeneca breached the UK pharmaceutical industry's code of practice by using a claim that misleadingly implied its Symbicort asthma drug was suitable for all newly diagnosed patients aged 12 years and over, the industry self-regulatory body ruled on Friday.
AstraZeneca's Datroway extends survival in aggressive breast cancer
AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat forms of the disease.
AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment
AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.
AstraZeneca downgraded by leading investment bank. Here's why
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) investors might want to take a deep breath. Deutsche Bank has turned bearish on the UK drugmaker, cutting its rating from Hold to Sell and trimming its price target to £105 from £110, well below the current share price of 12,548p (down 1%).
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve
AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.
AstraZeneca's drug pricing deal with Trump far from clear result, say analysts
Following AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) agreement with the US government on 'most favoured nation' drug pricing at the end of last week, analysts said the discounts were not as big as some were expecting but will still hit profits. The White House announced the deal on Friday, after markets closed in New York, with confirmation of the deal shared with investors on Monday.
AstraZeneca agrees to offer US discounts in exchange for no tariffs
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has become the second giant drugmaker to announce a drug pricing deal with the US government, after Pfizer's deal two weeks ago. Pascal Soriot, the CEO of the Anglo-Swedish pharmaceutical group, met President Donald Trump on Friday to confirm a range of measures, including offering discounts of up to 80% on its medicines under prescriptions for chronic diseases and making its drugs available on the TrumpRx.gov direct purchasing platform.
Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump
AstraZeneca CEO Pascal Soriot looked relaxed standing in the Oval Office on Friday as U.S. President Donald Trump unveiled a medicine deal that will lower drug prices for millions of Americans.
Trump announces drug-pricing deal with pharma giant
President Trump details a new drug-pricing deal with AstraZeneca, and Fox News political analyst Lisa Boothe reacts on 'The Evening Edit.'
